RESUMO
BACKGROUND: The World Health Organization (WHO) recommends parasite-based diagnosis of malaria. In recent years, there has been surge in the use of various kinds of nucleic-acid amplification based tests (NAATs) for detection and identification of Plasmodium spp. to support clinical care in high-resource settings and clinical and epidemiological research worldwide. However, these tests are not without challenges, including lack (or limited use) of standards and lack of reproducibility, due in part to variation in protocols amongst laboratories. Therefore, there is a need for rigorous quality control, including a robust external quality assessment (EQA) scheme targeted towards malaria NAATs. To this effect, the WHO Global Malaria Programme worked with the UK National External Quality Assessment Scheme (UK NEQAS) Parasitology and with technical experts to launch a global NAAT EQA scheme in January 2017. METHODS: Panels of NAAT EQA specimens containing five major species of human-infecting Plasmodium at various parasite concentrations and negative samples were created in lyophilized blood (LB) and dried blood spot (DBS) formats. Two distributions per year were sent, containing five LB and five DBS specimens. Samples were tested and validated by six expert referee laboratories prior to distribution. Between 37 and 45 laboratories participated in each distribution and submitted results using the online submission portal of UK NEQAS. Participants were scored based on their laboratory's stated capacity to identify Plasmodium species, and individual laboratory reports were sent which included performance comparison with anonymized peers. RESULTS: Analysis of the first three distributions revealed that the factors that most significantly affected performance were sample format (DBS vs LB), species and parasite density, while laboratory location and the reported methodology used (type of nucleic acid extraction, amplification, or DNA vs RNA target) did not significantly affect performance. Referee laboratories performed better than non-referee laboratories. CONCLUSIONS: Globally, malaria NAAT assays now inform a range of clinical, epidemiological and research investigations. EQA schemes offer a way for laboratories to assess and improve their performance, which is critical to safeguarding the reliability of data and diagnoses especially in situations where various NAAT methodologies and protocols are in use.
Assuntos
Testes Diagnósticos de Rotina/estatística & dados numéricos , Malária/diagnóstico , Técnicas de Amplificação de Ácido Nucleico/estatística & dados numéricos , Plasmodium/isolamento & purificação , Garantia da Qualidade dos Cuidados de Saúde/estatística & dados numéricos , Humanos , Controle de Qualidade , Reprodutibilidade dos Testes , Organização Mundial da SaúdeRESUMO
Background: In Zimbabwe, while the Xpert MTB/RIF assay is being used for diagnosing tuberculosis and rifampicin-resistance, re-treatment tuberculosis (TB) patients are still expected to have culture and drug sensitivity testing (CDST) performed at national reference laboratories for confirmation. The study aim was to document the Xpert MTB/RIF assay scale-up and assess how the CDST system functioned for re-treatment TB patients. Methods: We performed an ecologic study using national aggregate data. Results: Use of the Xpert MTB/RIF assay increased from 11 829 to 68 153 between 2012 and 2016. Xpert assays worked well, with successful tests in more than 90% of cases, TB detection rates at 15-17% and rifampicin resistance in <10%. During Xpert scale-up, the number of sputum specimens from re-treatment TB patients reaching national reference laboratories for CDST increased from 12% to 51%. In terms of laboratory performance, culture contamination increased from 3% to 17%, positive cultures from 13% to 17% and successful CDST from 6% to 14%: the proportion of CDST showing any resistance to rifampicin averaged 44%. From 2009 to 2016, the proportion of notified re-treatment TB patients with successful CDST increased from <1% to 7%. Conclusions: While components of Zimbabwe's CDST system for re-treatment TB patients showed some changes during the scale-up of the Xpert MTB/RIF assay, overall performance was poor. The country must either invest in improving CDST performance or in advanced molecular diagnostic technology.
Assuntos
Antibióticos Antituberculose/farmacologia , Mycobacterium tuberculosis/isolamento & purificação , Técnicas de Amplificação de Ácido Nucleico , Saúde Pública , Rifampina/farmacologia , Escarro/microbiologia , Tuberculose Resistente a Múltiplos Medicamentos/diagnóstico , Antibióticos Antituberculose/uso terapêutico , Inquéritos Epidemiológicos , Humanos , Mycobacterium tuberculosis/efeitos dos fármacos , Técnicas de Amplificação de Ácido Nucleico/economia , Técnicas de Amplificação de Ácido Nucleico/estatística & dados numéricos , Saúde Pública/economia , Rifampina/uso terapêutico , Sensibilidade e Especificidade , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Tuberculose Resistente a Múltiplos Medicamentos/epidemiologia , Zimbábue/epidemiologiaRESUMO
OBJECTIVE: To assess the current served available market of tuberculosis (TB) diagnostics in South Africa in the public and private sectors. DESIGN: Public and private sector test volumes and unit costs were collected for tuberculin skin tests, interferon-gamma release assays, smear microscopy, culture, speciation, Xpert MTB/RIF, other nucleic acid amplification tests, drug susceptibility testing and adenosine deaminase tests. RESULTS: In 2012, during Xpert scale-up, the public and private sectors performed a total of 9.2 million TB diagnostic tests, at an estimated total value of US$98 million. The public sector accounted for 93% of the overall test volume and value. There were no major differences in the types of tests performed in both sectors, with microscopy and culture accounting for the majority of tests performed (72%). In 2013, the public sector market value increased to US$101 million (a 10% increase over 2012): Xpert volumes increased by 166%, while total TB test volumes decreased by 12% compared to 2012. CONCLUSION: South Africa has a substantial TB diagnostic market in terms of both volume and value. The roll-out of Xpert provides insights into how markets change in volume and value with the introduction of new tools.
Assuntos
Antituberculosos/farmacologia , Testes Diagnósticos de Rotina/estatística & dados numéricos , Mycobacterium tuberculosis/efeitos dos fármacos , Tuberculose/diagnóstico , Testes Diagnósticos de Rotina/economia , Humanos , Testes de Liberação de Interferon-gama/economia , Testes de Liberação de Interferon-gama/estatística & dados numéricos , Testes de Sensibilidade Microbiana , Microscopia/economia , Microscopia/estatística & dados numéricos , Mycobacterium tuberculosis/isolamento & purificação , Técnicas de Amplificação de Ácido Nucleico/economia , Técnicas de Amplificação de Ácido Nucleico/estatística & dados numéricos , África do Sul , Escarro/microbiologia , Teste Tuberculínico/economia , Teste Tuberculínico/estatística & dados numéricos , Tuberculose/economia , Tuberculose/microbiologiaRESUMO
OBJECTIVE: A service evaluation of the new Gen-Probe APTIMA nucleic acid amplification test was performed to determine the prevalence of Trichomonas vaginalis (TV) infection in a UK sexual health clinic and identify risk factors to inform an appropriate TV screening strategy. METHOD: Unselected patients presenting with a new clinical episode were offered TV testing with Gen Probe transcription-mediated amplification (TV TMA) in addition to routine sexually transmitted infection screening. Asymptomatic females provided a self-collected vulvovaginal specimen and asymptomatic men a first-void urine sample. Symptomatic patients were examined and a urethral swab taken from men and two posterior vaginal swabs from females; one for culture and one for TV TMA testing. Demographic and clinical data were collected on all patients positive for TV infection and 100 randomly selected TV-negative controls. RESULTS: 3503 patients underwent TV TMA testing during the evaluation period. The prevalence of TV infection was 21/1483, 1.4% (95% CI 0.9% to 2.2%) in men and 72/2020, 3.6% (95% CI 2.8% to 4.5%) in women. The rate of TV positivity was higher in Black Caribbean patients compared with Caucasian patients (men 5.4% vs 0.1%, p<0.001; women 9.0% vs 1.2%, p<0.001). TV TMA detected an additional 16 infections (38%) in symptomatic women compared with culture. CONCLUSIONS: While screening all patients with TV TMA will identify more TV infections, the UK prevalence remains low and this approach is unlikely to be cost effective. In addition to testing symptomatic patients, targeted testing of high-risk asymptomatic groups using TV TMA should be considered.
Assuntos
Testes Diagnósticos de Rotina/métodos , Pesquisa sobre Serviços de Saúde , Técnicas de Amplificação de Ácido Nucleico/métodos , Tricomoníase/diagnóstico , Tricomoníase/epidemiologia , Trichomonas vaginalis/isolamento & purificação , Adolescente , Adulto , Análise Custo-Benefício , Testes Diagnósticos de Rotina/economia , Testes Diagnósticos de Rotina/estatística & dados numéricos , Feminino , Humanos , Masculino , Técnicas de Amplificação de Ácido Nucleico/economia , Técnicas de Amplificação de Ácido Nucleico/estatística & dados numéricos , Prevalência , Tricomoníase/parasitologia , Trichomonas vaginalis/genética , Reino Unido/epidemiologia , Uretra/parasitologia , Urina/parasitologia , Vagina/parasitologia , Vulva/parasitologia , Adulto JovemRESUMO
Increasing emphasis on the use of molecular tests in a histocompatibility and immunogenetics laboratory (HIL) poses a potential problem of lack of sufficient DNA to perform multiple genetic analyses. In this study, we report the feasibility, fidelity and utility of multiple displacement amplification (MDA) method to perform whole-genome amplification (WGA) to generate DNA specimens that can be analyzed by multiple molecular techniques and can be used for different clinical tests offered by an HIL. The MDA-generated DNA when compared with the native DNA showed 100% congruency in genotyping of 37 genes/loci using multiple downstream molecular techniques: sequence-based typing and sequence-specific primer-based typing for 5 human leukocyte antigen (HLA) class I and II genes (HLA-A, B, C, DRB1 and DQB1), luminex-based sequence-specific oligonucleotide (SSO) genotyping for a panel of 16 killer immunoglobulin-like receptor (KIR) genes and automated fragment size analysis for a panel of 15 short tandem repeat (STR) loci and amelogenin gene. For post-allogeneic hematopoietic cell transplantation (HCT) chimerism analysis, MDA-generated DNA appeared useful for enriching pre-transplant DNA but not for enriching post-transplant chimeric DNA. Overall, our results show that MDA-based WGA could generate DNA of high yield and fidelity that can be used for various clinical tests and research purposes.
Assuntos
Impressões Digitais de DNA/métodos , DNA/análise , Genoma Humano , Técnicas de Amplificação de Ácido Nucleico/métodos , Amelogenina/genética , Amelogenina/imunologia , DNA/genética , Primers do DNA , Perfilação da Expressão Gênica , Loci Gênicos , Estudo de Associação Genômica Ampla , Antígenos HLA/genética , Antígenos HLA/imunologia , Transplante de Células-Tronco Hematopoéticas , Teste de Histocompatibilidade , Humanos , Técnicas de Amplificação de Ácido Nucleico/estatística & dados numéricos , Receptores KIR/genética , Receptores KIR/imunologia , Análise de Sequência de DNA , Sequências de Repetição em Tandem , Transplante HomólogoAssuntos
Chlamydia trachomatis/isolamento & purificação , Ensaio de Imunoadsorção Enzimática/estatística & dados numéricos , Técnicas de Amplificação de Ácido Nucleico/estatística & dados numéricos , Infecções por Chlamydia/diagnóstico , Feminino , Humanos , Técnicas de Amplificação de Ácido Nucleico/economia , Medicina Estatal , Reino UnidoRESUMO
Complementarity-determining region 3 (CDR3) length distribution analysis explores the diversity of the T cell receptor (TCR) and immunoglobulin (Ig) repertoire at the transcriptome level. Studies of the CDR3, the most hypervariable part of these molecules, have been frequently used to identify recruitment of T and B cell clones involved in immunological responses. CDR3 length distribution analysis gives a clear perception of repertoire variations between individuals and over time. However, the complexity of CDR3 length distribution patterns and the high number of possible repertoire alterations per individual called for the development of robust data analysis methods. The goal of these methods is to identify, quantify and statistically assess differences between repertoires so as to offer a better diagnostic or predictive tool for pathologies involving the immune system. In this review we will explain the benefit of analyzing CDR3 length distribution for the study of immune cell diversity. We will start by describing this technology and its associated data processing, and will subsequently focus on the statistical methods used to compare CDR3 length distribution patterns. Finally, we will address the various methods for assessing CDR3 length distribution gene signatures in pathological states.
Assuntos
Linfócitos B/química , Linfócitos B/metabolismo , Regiões Determinantes de Complementaridade/biossíntese , Regiões Determinantes de Complementaridade/química , Técnicas Imunológicas/estatística & dados numéricos , Técnicas de Amplificação de Ácido Nucleico/estatística & dados numéricos , Linfócitos T/química , Linfócitos T/metabolismo , Animais , Linfócitos B/imunologia , Regiões Determinantes de Complementaridade/genética , Regiões Determinantes de Complementaridade/isolamento & purificação , Humanos , Linfócitos T/imunologiaRESUMO
BACKGROUND AND OBJECTIVES: To reduce the risk of transfusion-transmissible viruses entering the blood supply, the nucleic acid amplification testing (NAT) was implemented to screen Scottish and Northern Irish blood donations in minipools. After 5 years of NAT for hepatitis C virus (HCV) and 2 years for human immunodeficiency virus-1 (HIV-1), the yield of serologically negative, nucleic acid positive 'window donations' and cost-benefit of NAT is under review. MATERIALS AND METHODS: When the Scottish National Blood Transfusion Service (SNBTS) implemented NAT in 1999, a fully automated 'black box' system was not available. Therefore, an 'in-house' assimilated NAT assay was developed, validated and implemented. The system is flexible and allows testing for additional viral markers to be introduced with relative ease. RESULTS: The HCV and HIV NAT assays have 95% detection levels of 7.25 IU/ml and 39.8 IU/ml, respectively, as determined by probit analysis. One HCV (1 in 1.9 million) and one HIV (1 in 0.77 million) window donation have been detected in 5 and 2 years, respectively, of NAT. CONCLUSION: The SNBTS NAT assays are robust and have performed consistently over the last 5 years. The design of the in-house system allowed HIV NAT to be added in 2003 at a relatively small additional cost per sample, although for both assays, the royalty fee far exceeds the cost of the test itself. Clearly NAT has a benefit in improving the safety of the blood supply although the risks of transfusion-transmitted viral infections, as reported in the Serious Hazards of Transfusion (SHOT) report, are extremely low. Also, in UK the yield of HCV antibody negative, NAT positive donations is far lower than predicted although the early detection of an HIV window period donation and the increase of HIV in the blood donor and general populations may provide a stronger case for HIV NAT. SUMMARY SENTENCE: The yield of HCV and HIV NAT in UK is significantly less than that anticipated from statistical models.
Assuntos
Doadores de Sangue , Transfusão de Sangue/normas , Infecções por HIV/diagnóstico , Hepatite C/diagnóstico , Técnicas de Amplificação de Ácido Nucleico/normas , Adulto , Transfusão de Sangue/economia , Transfusão de Sangue/métodos , Análise Custo-Benefício , Feminino , Soronegatividade para HIV , Humanos , Irlanda , Masculino , Pessoa de Meia-Idade , Técnicas de Amplificação de Ácido Nucleico/economia , Técnicas de Amplificação de Ácido Nucleico/estatística & dados numéricos , Escócia , Sensibilidade e Especificidade , Testes SorológicosRESUMO
Nucleic acid amplification tests (NAATs), which are highly sensitive and specific, have provided the ability to use alternative sam-ple types for the diagnosis of sexually transmitted infections (STIs). Self-collected genital specimens, such as urine or even vaginal swabs, can now be accurately used to diagnose gonorrhea or chlamydia infections. In many cases, use of these sample types can decrease the necessity for a clinician to perform a pelvic examination on women or to collect a urethral swab from men, thus extending the diagnostic capability for detecting these infections to nonclinic screening venues. As most chlamydia infections and many gonorrhea infections are asymptomatic, the use of NAATs for self-collected samples greatly increases the types and numbers of patients that can be screened outside of clinic settings. Self-sampling also allows clinicians to easily screen patients in the clinic for STIs who are not presenting for pelvic or urogenital examinations. The application of NAATs to self-collected specimens has the potential to augment public health programs designed to control the epidemic of STIs in the community.